Consumption of illicit drugs is generally underestimated as cause of road accidents. French legislation does not give the police authority to carry out their detection at once. If the regulation concerning driving and drinking is on the way of an hardening, a debate comes into being about the suppression of the penalization for consumption of some drugs whereas their involvement in road fatalities seems to be important. The influence of medicinal drugs on driver's behaviour forms the subject matter of many experimental studies, but the lack of a common methodology for testing their side effects prevents any possibility of categorization of the medicinal drugs depending of their risk for driving. This common methodology should include tests for the evaluation of risk taking and not only test for the detection of sedative effects. If self prescription and misuse of some medicinal drugs is often involved, if the prescription of some others should be allowed only for non drivers, it should be suitable to take into account the notions of therapeutical benefits and of preservation of social and professional integrity by the way of driving.
Download full-text PDF |
Source |
---|
Arterioscler Thromb Vasc Biol
January 2025
Research Center of Clinical Medicine, Affiliated Hospital, Nantong University, China. (X.W., D.L.).
Background: Hyperglycemia is a major contributor to endothelial dysfunction and blood vessel damage, leading to severe diabetic microvascular complications. Despite the growing body of research on the underlying mechanisms of endothelial cell (EC) dysfunction, the available drugs based on current knowledge fall short of effectively alleviating these complications. Therefore, our endeavor to explore novel insights into the cellular and molecular mechanisms of endothelial dysfunction is crucial for the field.
View Article and Find Full Text PDFCurr Med Res Opin
January 2025
Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico Gemelli IRCCS, Rome, Italy.
Introduction: The management of patients with Polycythemia Vera (PV) traditionally includes low-dose aspirin, phlebotomy, and cytoreductive therapy for high-risk individuals. Recent evidence suggests that cytoreductive treatment may be warranted for patients with additional risk factors beyond the traditional criteria of a history of thrombosis and age over 60 years. Introducing new therapeutic agents, including ropeginterferon alfa-2b and ruxolitinib, enables a more personalized treatment approach tailored to individual patient characteristics.
View Article and Find Full Text PDFFront Med (Lausanne)
January 2025
The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
Background: Sodium-glucose co-transporter two inhibitors (SGLT2is) are widely used in clinical practice due to their proven cardiovascular and renal benefits. However, various adverse drug reactions (ADRs) have been reported. This study aims to systematically update the ADRs associated with SGLT2is and identify the differences among various SGLT2is acovigilance of various SGLT-2 inhibitors.
View Article and Find Full Text PDFHeliyon
January 2025
Department of Pharmacy, Shanghai Changhai Hospital, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
Currently, the trials found that the clinical efficacy of molnupiravir is lower than ritonavir-boosted nirmatrelvir. An explanation for these different efficacies in clinical treatments is still limited. The analysis method was developed and validated to simultaneously quantify nirmatrelvir, ritonavir, and beta-D-N4-hydroxycytidine (NHC) in human plasma and bronchoalveolar lavage fluid (BALF) by electrospray ionization mass spectrometry.
View Article and Find Full Text PDFGlob Reg Health Technol Assess
January 2025
Omakase Consulting S.L., Barcelona - Spain.
Background: Activated phosphoinositide 3-kinase (PI3K) δ Syndrome (APDS) is an ultra-rare, potentially life-threatening disease that lacks approved treatments in Spain. This study aimed to apply Multi-Criteria Decision Analysis (MCDA) to assess the value of the first pharmacological treatment for APDS in Spain.
Methods: A multidisciplinary group of 8 experts evaluated the selective PI3Kδ inhibitor leniolisib against Standard of Care (SoC).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!